arrow_back Back Filing freshness 20-F FY 2025 SEC EDGAR

Burning Rock Biotech Ltd

BNR
$9.00 ▼ -0.05 (-0.55%) at close
Healthcare ·Services-Medical Laboratories ·USServices-Medical Laboratories
7 Visible periods
21 Metrics
Peer-ranked Benchmarks
Price Chart
22
Health
Poor
Bearish
auto_awesome

Analytical Summary

Burning Rock Biotech Ltd faces fundamental challenges with weakness in Profit Margin (%) and Operating Margin (%). The fundamentals warrant careful consideration of downside risks.

Market Cap
Dividend Yield
Revenue Growth 9.2%
Op. Margin -10.2%
ROIC -8.1%
FCF / Share
Trailing P/E
Price / Book
FCF Yield
Debt / Equity
info Valuation on last close. End-of-day price, Aug 7, 2026.

7-Year Financial Trajectory

Annual
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$77.16M
↑ +9.2%
Net Income Profit after all expenses
$-7.92M
↑ +83.3%
Operating Margin Operating profit as % of sales
-10.2%
↑ +85.3% 15th
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Operating Margin (%)Operating Margin (%) is in the bottom quartile
  • Profit Margin (%)Profit Margin (%) is in the bottom quartile

Health Breakdown

Profitability
15
Returns
34
Financial Health
3
Cash Quality
44

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 7 years · 7 quarters